“Hilja’s deep expertise in commercializing diagnostics will be invaluable as we aim to launch our first diagnostic products next year,” says Elypta CEO Karl Bergman.

Hilja Ibert 

Dr. Ibert has over 30 years of experience in clinical diagnostics, having held senior positions at international companies, including Hologic, Becton Dickinson, and bioMérieux. She recently served as CEO and now chairs the Board of Gentian Diagnostics ASA, where she played a key role in the company’s growth and success. She is also a board member at Gradientech, a company specializing in ultra-rapid antibiotic susceptibility testing. Dr. Ibert holds a Ph.D. in Microbiology and a degree in Nutritional Sciences from the Rheinische Friedrich Wilhelms Universität of Bonn, Germany.

“I am excited to join Elypta at this pivotal moment as the company prepares to bring its diagnostic solutions to market, and I look forward to contributing to Elypta’s commercial success,” says Ibert.